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RESUMEN

El propósito de este estudio fue examinar las variabilidades del ciclo menstrual o las variaciones en los niveles séricos de HE4 en mujeres con enfermedades ováricas benignas. Se realizó un estudio prospectivo en la Clínica Universitaria de Obstetricia y Ginecología en Skopje. Noventa y cuatro pacientes divididos en dos grupos fueron incluidos en el estudio. Un grupo estuvo formado por 37 pacientes con endometriosis ovárica, y el otro por 57 pacientes con "otras masas pélvicas benignas". Luego de la detección ultrasónica de una masa pélvica de posible origen ovárico, se obtuvieron muestras de todos los pacientes para investigar el comportamiento sérico de HE4 y CA125. Todos los casos fueron sometidos a cirugía para retirar la masa pélvica, además de la subsecuente evaluación histológica como criterio para la clasificación en grupos. No hubo diferencias significativas de HE4 en los niveles sanguíneos entre las fases folicular (FF) y lútea (FL) en los pacientes con endometriosis ovárica (t35 = 0.147, p = 0.884) y las "otras masas pélvicas benignas" (U = 424.5, p = 0.730). No hubo diferencias significati-vas en los niveles séricos de HE4 en la fase folicular entre los dos grupos (U =
222
INTRODUCTION
Ovarian cancer is a common gynaecologic cancer with a worse prognosis if detected in the advanced stages. The estimated annual incidents are 238 700 cases worldwide and 151 900 patients die every year under the diagnosis of ovarian cancer (1) . Carbohydrate antigen-125 marker is a far widely used biomarker in the management of women with an adnexal mass, but it shows low specificity, being elevated in benign ovarian diseases, gynaecological and some nongynaecological cancers, as well as in liver diseases (2−4). Furthermore, it has been reported to show menstrual cycle variabilities (5) .
The novel biomarker HE4 (human epididymis protein 4) is a member of the family of whey acidic proteins. Over-expression of the HE4 has been found in serous and endometrioid ovarian carcinoma (6) . Its use has been intensively studied and has been shown to overcome the classification power of CA125 (7, 8) . Previous studies have shown: age, fertility status, menopause, smoking, ethnicity and renal function may affect serum HE4 levels (9−11).
The primary aim of this study was to examine the menstrual cycle variabilities of serum HE4 levels in women with benign ovarian pathology.
SUBJECTS AND METHODS
A prospective, observational study was conducted at the University Clinic of Obstetrics and Gynaecology in Skopje. The study was approved by the Ethics committee at the Ministry of Health in the Republic of Macedonia. Only patients who agreed to sign the informed consent were included in the trial. Ninety-four premenopausal women were included in this study. They were separated into two groups: 37 with ovarian endometriosis, and 57 with "other benign pelvic masses". To be eligible for enrolment in this study, all the patients were required to be 18 years of age or older with regular menstrual cycles, to have an ultrasonography scan showing an ovarian mass and to be scheduled for a surgical intervention. From this study, patients younger than 18 years with irregular menstrual cycles, patients with prior oophorectomies, patients with current or past malignancy, renal failure or disease, current hormonal therapy and pregnancy, were excluded. Histology finding was referent for the group classification.
Ultrasound investigation was performed using Voluson E8 (General Electrics), 4−9 MHz RIC5-9D vaginal transducers in each patient in supine position. Ultrasonography was performed at most six weeks prior to the surgical intervention. Sera samples were analysed using the Architect CA125 II and Architect HE4 reagents on an Abbott Platform (Abbott Diagnostics, Wiesbaden, Germany) and following the manufacturer's instructions. All the patients underwent surgical removal of the ovarian mass.
Statistical analyses were carried out using the following software SPSS 22.0 (IBM Corp. Released 2013. Armonk, NY). The statistical tests used in the analyses were as follows: Man Whitney U test, Pearson correlation, Spearman rank correlation and t-test. The level of significance α was set at 5%.
RESULTS
We examined 94 patients who were divided into two groups. The first group included 37 (39.4%) patients with endometriosis and the second group included 57 (60.6%) patients with the "other benign pelvic masses". Out of the patients, 15 (26.3%) had epithelial, 19 (33.3%) had functional, 4 (7.0%) had germinative, 13 (22.8%) had inflammatory tumours, 2 (3.5%) had uterine myomas, 3 (5.3%) had paraovarial and 1 (1.8%) had stromal tumour. Descriptive statistics were shown in Table 1 . The difference in the level of the marker HE4 and CA125 between the patients with endometriosis and "other benign pelvic masses" was tested. For the patients with endometriosis (n = 37), marker HE4 was associated with lower level (Mdn = 35.50) pmol/L in comparison with patients with "other benign pelvic masses" (n = 57) where marker HE4 was associated with higher level (Mdn = 40.30) pmol/L. To test if there was a significant difference in the level of the marker HE4 between the two groups, a non-parametric Mann-Whitney U test was done.
HE4 Variations during Menstrual Cycle
Shapiro-Wilk's test (p < 0.05), an inspection of the skew-ness and kurtosis measures, visual inspection of their his-tograms, normal Q-Q plots and box plots showed that the sample data were not normally distributed. A nonparametric Levene's test was used to verify the homogeneity of the vari-ance (p = 0.119). This difference was significant (U = 752.5, p = 0.019 two-tailed). The Glass rank biserial correlation = 0.286, with a small effect in Cohen's (1988) classification (Fig. 1) .
Mann-Whitney U test done showed that this difference was not significant (U = 1,218.5, p = 0.204, two-tailed).
There was a difference in the level of the marker HE4 between the follicular phase of the menstrual cycle and the luteal phase of the menstrual cycle for the patients with endometriosis and the "other benign pelvic masses". To test the hypothesis that level of the marker HE4 (M = 37.44 pmol/Lfollicular, M = 36.93 pmol/L -luteal) is different for the phases of menstrual cycle for the patients with endometrioses, an independent t-test was performed which was statistically not significant (t (35) = 0.147, p = 0.884, two-tailed). For the "other benign pelvic masses" (Med = 41.40 pmol/L -follicular, Med = 40.20 pmol/L -luteal) a non-parametric Mann-Whitney U test was performed which was also statistically not significant (U = 424.5, p = 0.730, two-tailed).
Tested differences for the maker CA125 between the follicular phase and the luteal phase of the menstrual cycle for the patients with endometrioses (M = 71.02 U/mL -follicular, M = 48.89 U/mL -luteal) and for the "other benign pelvic masses" (Med = 40.20 U/mL -follicular, Med = 22.90 U/mL -luteal), were statistically not significant (t35 = 1.336, p = 0.19, two-tailed) for the patients with endometriosis, and (U = 289.5, p = 0.069, two-tailed) for the patients with the "other benign pelvic masses".
For the phases of the menstrual cycle, follicular and luteal, we tested the difference in the level of the marker HE4 and the marker CA125 between the patients with endometriosis and the "other benign pelvic masses". For the phases of the menstrual cycle, to test the hypothesis that the level of marker HE4 for the patients with endometriosis (n = 14), (Mdn = 36.00 pmol/L -follicular phase) and (n = 23), (Mdn = 35.50 pmol/L -luteal phase) was significantly different for the patients with the "other benign pelvic masses" (n = 26), (Mdn = 41.40 pmol/L -follicular phase) and (n = 31), (Mdn = 40.20 pmol/L -luteal phase), respectively, a non-parametric On the contrary, for the marker CA125, there was a difference in the level between the patients with endometriosis (Mdn = 35.40) U/mL in comparison with the patients with the "other benign pelvic masses" (Mdn = 27.50) U/mL. The Mann-Whitney test was performed. Shapiro-Wilk's test (p < 0.05), inspection of the skewness and kurtosis measures, visual inspection of their histograms, normal Q-Q plots and box plots showed that the sample data were not normally distributed for both phases. A non-parametric Levene's test was used to verify the homogeneity of the variance (p = 0.205) for the follicular phase and (p = 0.387) for the luteal phase. The follicular phase difference was not significant: (U = 222.0; p = 0.266 (exact significance, two-tailed), while for the luteal phase level of the marker HE4 for "other benign pelvic masses" (Mdn = 40.20) pmol/L was significantly higher than the level for endometriosis (Mdn = 35.50) pmol/L (U = 469.5, p = 0.048, two-tailed). The Glass rank biserial correlation was 0.317, suggesting a medium effect based on Cohen's (1988) classification (Fig. 2) .
raised (> 35 U/mL). As we can see from the scatter plot, only in four cases was the level of the marker HE4 above 70 pmol/ L and all the cases were from the "other benign pelvic masses" group. Of the four cases, two were epithelial tumours, one was an inflammatory tumour and one case was a uterine myoma. Two cases each were in the follicular and the luteal phases of the menstrual cycle. The difference in the level of the marker CA125 between endometriosis, and the "other benign pelvic masses" was not significant for both phases: (U = 173.0, p = 0.812) [exact significance, two-tailed] for the follicular phase, and U = 250.5, p = 0.064 (two-tailed) for the luteal phase.
The correlations among markers HE4 and CA125 for the patients with endometriosis in the follicular phase of the menstrual cycle and the luteal phase of the menstrual cycle are shown in Table 2 . Both correlations are not significant p = 0.398 for the follicular phase, p = 0.648 for the luteal phase.
The correlations among markers HE4 and CA125 for the patients with the "other benign pelvic masses" in the follicular phase of the menstrual cycle and the luteal phase of the menstrual cycle are shown in Table 3 .
The correlation between HE4 and CA125 in the follicular phase of the menstrual cycle is significant p = 0.020, while the correlation in the luteal phase is not significant (p = 0.236). Figure 3 , shows the scatter plot for the levels of the marker HE4 for the cases where marker CA125 was abnormally 
DISCUSSION
In this study, we found that HE4 had a higher median in women with the "other benign pelvic mass" group in comparison with those with endometriosis (40.30 vs 35.50 pmol/L), and this difference was statistically significant (p < 0.05). Among the patients with abnormal CA125 levels (> 35 U/mL), we detected four patients with HE4 levels above 70 pmol/L and all of them represented the "other benign pelvic mass" group. Of these four cases, two were epithelial cystadenomas, one was an ovarian abscess, and one was uterine myoma. For the patients with epithelial cystadenomas, the level of HE4 was double and its upper referent value was 70 pmol/L whereas CA 125 was almost 30 times higher than its upper referent value (35 U/mL). Similarly, for the patient with uterine myoma, a slightly elevated level of HE4 went along with 40 times higher CA125. Furthermore, our analyses showed that the menstrual cycle did not affect the variations in the HE4 serum levels in both groups (ie the patients with endometriosis and the "other benign pelvic mass". This is in line with the findings already reported for the patients with endometriosis (12). Mckinnon et al came to the same conclusions regarding women with endometriosis, but they analysed HE4 from the peritoneal fluid (13) . However, Anastasi et al study of 40 women divided into two groups, reported menstrual cycle phase-dependent variability, but only for women under the age of 35 years (14) .
To our knowledge, our study is one of the first to investigate the menstrual cycle variations in patients with a benign ovarian disease, other than endometriotic tumours. The present study demonstrates that HE4 testing in women with ovarian endometriosis, as well as in women with the rest of benign ovarian pathology, can be carried out in any phase of the menstrual cycle, extending the benefits of HE4 use in clinical practice. We have performed the same analyses for CA125 serum levels and concluded that CA125 can be measured regardless of the variations irrespective in the menstrual cycle. On comparing the HE4 serum levels in the follicular and luteal phases among the patients with ovarian endometriosis and the "other benign pelvic mass", we found higher HE4 levels in the luteal phase in the patients with the "other benign pelvic mass" than in the patients with endometriosis, and this difference was statistically significant. No statistical significance was detected for CA125.
CONCLUSION
Human epididymis protein 4; is a robust biochemical marker and could be tested regardless of the variations in the human menstrual cycle.
